Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series-Reference-Cited by-同舟云学术

Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

Published:2022-09-22 Issue:5 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Ding Xinjing¹,Ding Jianghua¹,Leng Zhaohui²,Song Yun²

Affiliation:

1. Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

2. Department of Hematology and Oncology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi 332000, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference26 articles.

1. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review);He;Int J Oncol,2021

2. Osimertinib in Untreated EGFR-Mutated Advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

3. Mechanisms of osimertinib resistance and emerging treatment options;Schmid;Lung Cancer,2020

4. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 Deletion or L858R Mutations;Lu;J Clin Oncol,2022

5. Furmonertinib: First Approval;Deeks;Drugs,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

2. Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report;Journal of Chemotherapy;2023-11

3. Osimertinib;Reactions Weekly;2023-02-18